Table 1.

PSA gene polymorphisms in controls and prostate cancer cases

Controls, N = 734* (%)Cases, N = 819* (%)OR (95% CI)P
rs925013
    AA495 (67)488 (60)Reference0.006
    AG208 (28)286 (35)1.4 (1.1-1.7)
    GG31 (4)45 (5)1.5 (0.9-2.4)
    AA495 (67)488 (60)Reference0.001
    AG, GG239 (32)331 (40)1.4 (1.1-1.7)
    AA, AG703 (96)774 (95)Reference0.2
    GG31 (4)45 (5)1.3 (0.8-2.1)
rs266882
    AA191 (27)210 (26)Reference0.3
    AG366 (51)400 (49)1.0 (0.8-0.3)
    GG156 (22)204 (25)1.2 (0.9-1.6)
    AA191 (27)210 (26)Reference0.7
    AG, GG522 (73)604 (74)1.1 (0.8-1.3)
    AA, AG557 (78)610 (75)Reference0.1
    GG156 (22)204 (25)1.2 (0.9-1.6)
  • * Number of subjects with at least one of the two variants measured.

  • ORs and 95% CIs from unconditional logistic regression analysis.

  • Test for association between genotype and prostate cancer risk (likelihood ratio test).